“…A second sub-group analysis based on study design revealed no significant differences (p = 0.53) in RDW values between prospective (SMD = 0.39; 95% CI 0.13 to 0.65, p = 0.002; I 2 = 76.1%, p < 0.001) and retrospective studies (SMD = 0.24; 95% CI −0.6 to 0.55, p = 0.12; I 2 = 93.8%, p < 0.001) (Figure 5), even though the effect size in retrospective studies was not statistically significant. Finally, 13 studies [14,44,45,48,51,52,54,[56][57][58][60][61][62] also reported RDW values based on disease severity. RDW values in OSAS subjects were significantly higher in comparison to non-OSAS controls, in a progressive manner, from mild (SMD = 0.18; 95% CI 0.05 to 0.314, p = 0.006; I 2 = 45.5%, p = 0.037, Figure 6A) to moderate (SMD = 0.39; 95% CI 0.10 to 0.67, p = 0.009; I 2 = 89.1%, p < 0.001, Figure 6B) and to severe disease (SMD = 0.56; 95% CI 0.30 to 0.81, p < 0.001; I 2 = 88.4%, p < 0.001, Figure 6C).…”